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ABSTRACT
Vascular endothelial growth factor A (VEGF-A) is a
potent secreted mitogen critical for physiological
and pathological angiogenesis. Regulation of VEGF-
A occurs at multiple levels, including transcription,
mRNA stabilization, splicing, translation and differ-
ential cellular localization of various isoforms.
Recent advances in our understanding of the post-
transcriptional regulation of VEGF-A are comprised
of the identification of stabilizing mRNA-binding
proteins and the discovery of two internal ribosomal
entry sites (IRES) as well as two alternative initiation
codons in the 5’UTR of the VEGF-A mRNA. We have
previously reported that VEGF-A translation initia-
tion at both the AUG and CUG codons is dependent
on the exon content of the coding region. In this
report, we show that the expression of different
VEGF-A isoforms is regulated by a small upstream
open reading frame (uORF) located within an inter-
nal ribosome entry site, which is translated through
a cap-independent mechanism. This uORF acts as a
cis-regulatory element that regulates negatively the
expression of the VEGF 121 isoform. Our data
provide a framework for understanding how VEGF-
A mRNAs are translated, and how the production of
the VEGF 121 isoform is secured under non-hypoxic
environmental conditions.
INTRODUCTION
The growth of blood vessels, a process known as
angiogenesis, is essential for organ growth and repair.
An imbalance in this process contributes to numerous
inﬂammatory, ischemic, immune and malignant disorders.
The vascular endothelial growth factor A (VEGF-A) is a
growth and survival factor for endothelial cells, playing an
essential role in numerous physiological and pathological
angiogenic processes throughout embryonic development
and during adulthood (1,2). In the quiescent vasculature
of adult organs, VEGF is produced at basal level and
protects endothelial cells from apoptosis. However, in a
number of physiological situations, such as oestrus in the
female reproductive organs, wound repair, adaptation
to hypoxia as well as in many pathological situations like
proliferative retinopathies, arthritis, psoriasis and of
course cancer, VEGF level increases (3–5). VEGF acts
as the key mediator of tumor angiogenesis by stimulating
the growth of new blood vessels from nearby capillaries
and providing tumors with access to oxygen and nutrients
they need to grow and metastasis.
Both the deletion of a single VEGF allele (6,7) and
modest VEGF over-expression (8) result in embryonic
lethality due to improper vascularization. These experi-
ments on transgenic mice have clearly demonstrated that
the expression level of VEGF is under very tight regulatory
control, at least during development. Numerous studies
have been devoted to understand the regulation of expres-
sion of this factor. The importance of regulating VEGF
expression is further demonstrated by comparative geno-
mic sequence analyses, which reveal the conservation of
regulatory elements throughout numerous species. These
elements are summarized in Figure 1.
(1) The TATA-less promoter region (P1) includes
consensus sites for transcription factor such as Sp1/Sp3,
ER, PRE, AP2, Egf1, STAT3 and HIF1 among many
others (9–13). Several studies have demonstrated that
numerous stimuli activate VEGF transcription, including
growth factors, hypoxia, hormones, oncogenes and tumor
suppressors (9,14).
(2) A second internal promoter (IP) located 633
nucleotides downstream from the P1, directs the tran-
scription of a truncated mRNA (15).
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gene are highly conserved between human, rodent, dog
and chicken. Alternative splicing gives rise to at least nine
diﬀerent transcript variants corresponding to nine poly-
peptide isoforms of 121, 145, 148, 162, 165, 165b, 183, 189
and 206 amino acids (AA) (16–22). While functions for all
isoforms have not yet been fully deﬁned, most VEGF
producing cells appear to preferentially express VEGF
121, VEGF 165 and VEGF 189. These three major
isoforms of VEGF have diﬀerent properties concerning
receptor binding and extracellular localization. VEGF 121
is fully diﬀusible, whereas VEGF 165 and 189 isoforms are
able to bind to heparan sulfate on the cell surface and in
the extracellular matrix (23). Each isoform contributes to
the formation of a VEGF gradient that is essential for the
process of tumor neo-vascularization. The more soluble
isoform acts at distal sites to promote vascular recruit-
ment, and the extracellular membrane-associated isoforms
promote local expansion of capillary beds (24).
(4) The coding region is ﬂanked by a long
50-untranslated region (50UTR). In human, this region
spans 1038 nucleotides and contains three in frame
alternative CUG start codons, the ﬁrst one located 539
nucleotides upstream from the classical AUG initiation
codon (25–27) and two internal ribosome entry sites
(IRESes) (15,28,29). The ﬁrst identiﬁed IRES (IRES A) is
located within the 300 nucleotides upstream of the AUG
start codon and IRES B, 377 nucleotides in length,
is located 24 nucleotides upstream of the ﬁrst CUG codon.
The two IRESes control translation at the two initiation
codons as demonstrated in vitro (15,28) and in vivo (30).
Translation initiated at the CUG codon directs the
synthesis of L-VEGF, a precursor further cleaved to
generate on one hand secreted VEGF and on the other
hand N-VEGF, a 23-kDa NH2-speciﬁc fragment of 206
AA, which remains intracellular (25,27,31). Translation
from the AUG codon at position 1038 only generates
secreted VEGF isoforms. Interestingly, mRNA tran-
scribed from the internal promoter lacks both IRES B
and the CUG start codons.
(5) The 1881bp-long 30-untranslated region (30UTR)
contains multiple alternative polyadenylation signals, and
a large number of AU-rich elements (AREs) (32,33).
VEGF mRNA stability is regulated in response to several
stimuli through the binding of stabilizing and destabilizing
proteins to ARE located in his 30UTR (34–39).
VEGF, which is regulated at every conceivable stage
of its production, thus represents a paradigm for gene
regulation.
We have previously reported that the initiation of
translation at both AUG and CUG codons is dependent
on the exon content of the coding region. In this work,
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Figure 1. VEGF gene structure. The VEGF genomic structure is schematized with 50UTR containing: P1, TATA less promoter region including
hypoxia responsive element (HRE) (13); IP, internal promoter directs the transcription of a truncated mRNA. Three coding exons are alternatively
spliced and give rise to several polypeptide, the most abundant are the 121, 165 and 189 amino acids isoforms. The 1038 nucleotides upstream from
the AUG contain two IRESes (A and B) and in frame CUGs translation initiation codons that direct the synthesis of L-VEGF, which cleavage
generates secreted-VEGF plus the intracellular N-VEGF.
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We have analyzed, for the two described transcription
initiation sites, the relationship between alternatively
spliced mRNAs and the use of alternative translation
initiationcodons.WeidentiﬁedanupstreamORF(uORF),
within the IRES A, which acts as a regulatory element
essential for the control of isoform expression.
MATERIAL AND METHODS
Plasmid constructions
The constructs p121mSPHA, p165mSPHA and
p189mSPHA (Figure 2A) containing the 50UTR, the
coding sequence of each vegf cDNA isoforms, the
mutation of the signal peptide and an hemaglutinine
(HA) tag at the 30end of the vegf cDNA; the construct
pminiVEGF (Figure 3B), which contains the vegf cDNA
until exon 4, the mutation of the signal peptide,
the genomic sequence between exon 4 and exon 8 and
an HA tag, and the constructs pAUG121mSPHA,
pAUG165mSPHA, pAUG189mSPHA (Figure 3A),
which start 24 nucleotides upstream from the AUG
codon, have already been described (40).
The constructs p50121, p50165, p05189 and pVCmSP
have already been described (28). The addition of VEGF
189, 165, 121 cDNAs sequence at the 30 extremity of the
CAT cDNA were obtained by PCR. Ampliﬁcation
products of the p50189, p50165 and p50121 plasmids with
the primers Ex5 sens and VEGF 30 reverse (Table 1) were
then digested at the BglII, and EcoRI sites and cloned into
the BglII and EcoRI digested pVCmSP to create the
plasmids pVCmSP189, pVCmSP165 and pVCmSP121,
respectively (Figure 2B).
To obtain plasmid pAUGminiVEGF the XbaI/BsmI
fragment of pAUG189mSPHA was inserted into XbaI/
BsmI digested pminiVEGF (Figure 3B).
To obtain pIP121mSPHA, pIP165mSPHA,
pIP189mSPHA and pIPminiVEGF, we digested a frag-
ment obtained by PCR ampliﬁcation of p189mSPHA with
forward primer XbaI-IP and reverse primer Ex4 rev
(Table 1), with XbaI/BsmI for insertion into XbaI/BsmI
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Figure 2. Eﬀect of VEGF-A alternative spliced sequences on the translation initiation. (A) Left, schematic representation of the constructs used for
transfection experiments. The 50UTR is shown as thickened line, the VEGF coding region is shown as a black box when beginning at the CUG and
white box when beginning at the AUG. The mutated signal sequence is represented as hatched box. A HA tag for immunoblot detection is present at
the 30 end. The two IRESes are represented. The constructs encode the three VEGF isoforms (p121mSPHA, p165mSPHA and p189mSPHA
numbered 1, 2 and 3) and give rise to the VEGF and the L-VEGF proteins. Right, constructs were transiently transfected into HeLa cells. Their
expression was analyzed by western immunoblotting using an anti-HA antibody. The CUGs represent L-VEGF proteins and the AUGs represent
VEGF proteins. (B) Left, schematic representation of the constructs used for transfection experiments. CAT reporter is shown as striped box in
frame with VEGF coding sequence, VEGF non-coding sequences are shown as thickened line. The constructs, encoding VEGF-CAT with alternative
spliced sequence of each isoform of 189, 165, 121 AA as non-coding sequence pVCmSP189, pVCmSP165 and pVCmSP121 numbered 1, 2 and 3.
Right, constructs were transiently transfected into HeLa cells. Their expression was analyzed by western immunoblotting using an anti-CAT
antibody. The CUGs represent L-VEGF-CAT fusion proteins and the AUGs represent VEGF-CAT fusion proteins.
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pminiVEGF, respectively (Figure 3A–C).
To obtain plasmid containing serial deletion from the
internal promoter, we digested plasmids p121mSPHA,
p165mSPHA p189mSPHA and pminiVEGF with XbaI/
BsmI, the fragment was gel puriﬁed. We digested with
XbaI/BsmI PCR products ampliﬁed with reverse primer
Ex4 rev and forward primer  50AUGXbaI,  100AU
GXbaI,  200AUGXbaI,  300AUGXbaI. Each fragment,
corresponding to each VEGF cDNA isoforms, was ligated
with fragments corresponding to each deletion. We obtain
the constructs: p-50AUG121mSPHA, p-100AUG121m
SPHA, p-200AUG121mSPHA, p-300AUG121mSPHA,
p-50AUG165mSPHA, p-100AUG165mSPHA, p-200A
UG165mSPHA, p-300AUG189mSPHA, p-50AUG189
mSPHA, p-100AUG189mSPHA, p-200AUG189mSPHA,
p-300AUG189mSPHA, p-50AUGminiVEGF, p-100
AUGminiVEGF, p-200AUGminiVEGF, p-300AUG
miniVEGF (Figure 4A).
All the uORF mutations were performed using site-
directed mutagenesis (QuickChange, Stratagene, La Jolla,
CA), the primers are described in the Table 1. To intro-
duce the mutation of the uORF’s start codon, we used
primer reverse and forward mATGu, with the plasmid
pIP121mSPHA, pIP165mSPHA pIP189mSPHA and
pIPminiVEGF, leading respectively to the constructs
pIP121mORFmSPHA, pIP165mORFmSPHA, pIP18m
ORF9mSPHA and pIPminiVEGF (Figure 4B and C).
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Figure 3. Role of the VEGF-A 50UTR on alternative translation initiation control. (A) Schematic representation of the constructs used for
transfection experiments: constructs, encoding each isoform and the VEGF minigene, beginning at the main promoter (p121mSPHA, p165mSPHA,
p189mSPHA and pminiVEGF, numbered 1), constructs beginning 24 nucleotides upstream from the AUG (pAUG121mSPHA, pAUG165mSPHA,
pAUG189mSPHA and pAUGminiVEGF, numbered 2), and constructs beginning at the internal promoter start site +633 (pIP121mSPHA,
pIP165mSPHA, pIP189mSPHA and pIPminiVEGF numbered 3). (B) Each plasmid were transiently transfected into HeLa cells. Their expression
was analyzed by western immunoblotting using an anti-HA antibody. An anti-b-actin was used to control protein loading. The constructs 1 give rise
to the VEGF and the L-VEGF proteins and the other constructs encode only the AUG initiated VEGF proteins. RPA analyses were performed to
normalize transfection with a vector speciﬁc probe to quantify mRNA and with a b-actin probe to control RNA quantity.
Table 1. Oligonucleotide sequences
Oligonucleotides Sequences (50!30)
Ex5 sens AAGAAAGATAGAGCAAGA
VEGF 30 REV TTTGAATTCTCACCGCCTCGGCTTGTC
XbaI IP ATATCTAGACGGGGCTCGC
GGCGTCGCACTGAAAC
Ex4 REV CTGCATTCACATTTGTTGTGCTGTAG
 50 AUGXbaI GCTCTAGAGCCGGAGAGGGAGCGCGAGC
 100 AUGXbaI GCTCTAGAAAGAGTAGCTCGCCGAGGCG
 200 AUGXbaI GCTCTAGAGGAAGCCGGGCTCATGGACG
 300 AUGXbaI GCTCTAGAGAAGTGCTAGCTCGGGCCG
mATGu GGAAGCCGGGCTCTTGGACGGGTGAGG
mSO CATGGACGGGGAGGCGGC
GGTGTGCGCAGAC
RT Ex4 sens CCAGATTATGCGGATCAAACC
RT 30HA REV TCACCGCCTCGGCTTGTCAC
Nucleic Acids Research, 2008, Vol. 36, No. 7 2437To obtain the construct pIPmSOmSP189HA, which
contains the mutation of uORF’s stop codon, we use
the plasmid pIP189mSPHA with the primer mSO
reverse and forward (Table 1). To obtain the other
isoform pIPmSOmSP121HA pIPmSOmSP165HA and
pIPmSOminiVEGF, we digeted a fragment obtained by
PCR ampliﬁcation of pIPmSOmSP189HA with forward
primer XbaI-intP and reverse primer Ex4 rev, with
XbaI/BsmI for insertion into XbaI/BsmI digested
pIP121mSPHA, pIP165mSPHA and pIPminiVEGF
(Figure 4B and C).
Cellculture
HeLa cell line, a human uterus carcinoma cell line of
epithelial origin (obtained from ATCC n8. CCL2
TM), were
maintained in DMEM supplemented with 10% FCS, 1%
glutamine, 1% amphotericin and 0.1% gentamycin. All
the cells were grown in a humidiﬁed atmosphere of 5%
CO2 at 378C.
For hypoxic conditions, HeLa cells were cultured at
378C with 5% CO2, 94% N2 and 1% O2 in a hypoxic
incubator (Binder GmbH, Tuttligen, France).
Transient transfection
Cells were seeded into 100mm dishes 1day prior to
transfection, allowed growing to 50–70% conﬂuency.
According to the manufacturer’s instructions, 8mgo f
plasmid were transfected into the cells with 16ml of the
JetPEI reagent (Polyplus Transfection Illkirch, France) in
NaCl. Cells lysates were prepared 24h posttransfection for
protein or mRNA quantiﬁcation and analysis.
SiRNA transfection
eIF4E targeting and duplex control siRNA (Dharmacon,
Lafayette, CO) were transfected in HeLa cells (5 10
5)
using Interferin (Polyplus Transfection Illkirch, France)
accordingthemanufacturer’sprotocol.After48h,cellswere
cotransfected (3mg of plasmids and 10 nM siRNA) with
Lipofectamine 2000 (Invitrogen, Cergy-Pontoise, France),
and harvested 24h later for protein and RNA analyses.
Protein extracts and western blotting
Western blotting was performed as previously des-
cribed (41). Brieﬂy, transfected cells were scraped in
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Figure 4. Analysis of the VEGF mRNA polyribosomal distribution. (A) Schematic representation of polysomal and free mRNAs distribution after
HeLa cells transfection. The diagram represents the polysome distribution proﬁles obtained after centrifugation of cytoplasmic lysates over sucrose
gradient then fractionated from top to bottom. RNA was isolated from each fraction and visualized on agarose gel by Sybr green staining. (B)
Schematic representation of the constructs used for transfection experiments: construct encoding each VEGF isoforms, beginning at the main
transcription start site (p121mSPHA, p165mSPHA and p189mSPHA, numbered 1, 2 and 3) or at internal promoter start site (pIP121mSPHA,
pIP165mSPHA, pIP189mSPHA numbered 4, 5 and 6) and the VEGF minigene beginning at internal promoter start site (pIPminiVEGF numbered 7).
(C) From each fraction, RNA was prepared for agarose gel analysis of 18S and 28S rRNAs (AG) and for northern blot (NB) of VEGF and b-actin
for lane 6. For the minigene construct (lane 7), RNA were analyzed by RT–PCR (RT) since it was diﬃcult to resolve them by northern blot analysis,
with primer that amplify fragments corresponding to each VEGF isoforms.
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resuspended in sample lysis buﬀer [20% (sodium
dodecyl sulfate) SDS, 50% glycerol, 50mM Tris
pH7.8, Bromophenol blue] in the presence of 1%
b-mercaptoethanol and 1% dithiothreitol 1M and sub-
jected to sonication. Total proteins were quantiﬁed by
BCA assay (Interchim, Montluc ¸ on, France). The 30mg
protein samples were heated for 2min at 958C and
separated by 12.5% polyacrylamide gel (PAGE), before
being transferred onto a nitrocellulose membrane.
HA-tagged VEGF proteins were detected using the HA
antibody (HA.11, BabCO Eurogentec, Herstal, Belgium)
(dilution 1:1000). CAT-fusion VEGF proteins were
detected using the rabbit polyclonal CAT antibody
prepared in the laboratory (dilution 1:10000). eiF4E
protein was detected using speciﬁc polyclonal antibody
(Cell Signaling, Danvers, MA) (dilution 1:1000). The
protein signal was normalized using an anti-b-actin
monoclonal antibody. (AC-15, Sigma-Aldrich, Lyon,
France) (dilution 1:10000). Signals were detected using a
chemiluminescence ECL kit (Amersham Pharmacia
Biotech, Piscataway, NJ).
Preparation of RNA probes forribonuclease
protection assays and northernblot
To quantify cell transfection, a probe designed for anneal
the 30 end of construct was ampliﬁed from p189PSmHA
using the forward primer CGGATCTTTTCCCTCTGC
CAA and the T7 containing reverse primer TAATACGA
CTCACTATAGGGCAAACTCTAAACCAAATACTC,
designed to amplify a 190-nt fragment spanning the
30UTR of the pSCT from the HA tag to the polyadenyla-
tion signal.
To normalize RPA quantiﬁcation, a b-actin probe was
designed using forward primer TGTACGCCAACACAG
TGCTGTC and T7 containing reverse primer TAAT
ACGACTCACTATAGGGTAGAAGCATTTGCGGT
GGACG to amplify a 250-nt fragment.
RNA probe labeled with Biotin-14-CTP (Invitrogen,
Cergy-Pontoise, France) were synthesized using an in vitro
transcription kit (Maxiscript; Ambion, Austin, TX).
Probes of validated length was gel-puriﬁed on 5%
polyacrylamide 8M urea gel, eluted in probe elution
buﬀer (Ambion, Austin, TX) overnight at 378C and
ethanol precipitated.
To analyze mRNAs distribution into polysomes, north-
ern blot was performed using a DNA probe ampliﬁed by
PCR from p189SPmHA with forward primer  50XbaI
and reverse primer Ex4 rev (Table 1). To prove mRNA
integrity, northern blot was performed using a DNA
probe ampliﬁed with the primers used for RPA probe
synthesis. After gel puriﬁcation, the fragment was labeled
using Biotin ULS labeled probe (Biotin ULS Labaling
Kit, Fermentas Canada, Ontario).
RNA preparation, Rnase protectionassay andnorthern blot
Total RNA was isolated from transiently transfected cells
with the Trizol reagent (Invitrogen, Cergy-Pontoise,
France) and treated with 1ml of DNA free (Ambion,
Austin, TX). RPA analysis was performed using the RPA
III kit (Ambion, Austin, TX) following the protocol
provided by the manufacturer. The hybridization was
carried out by overnight incubation at 428C of 1ng of
labeled probe and 2mg of RNA samples. The hybridiza-
tion mixture was then treated with ribonuclease A/T1 mix
for 30min at 378C. Digested samples were ethanol
precipitated and separated on a 5% polyacrylamide 8M
urea gel followed by semi-dry electroblotting onto
Positively Charged Nylon Membranes (BrightStar-Plus,
Ambion, Austin, TX). After transfer, membranes were
UV cross-linked and the bands were visualized using
secondary chemiluminescent detection (BrightStar
BioDetect, Ambion, Austin, TX).
Integrity of each mRNAs was veriﬁed by northern blot
as previously described (42).
Sucrose-gradient fractionation, polysome-associated
RNA analysis, northernblot and RT–PCR
Sucrose-gradient fractionation was performed essentially
as described. Extracts from HeLa cells were prepared by
lysis at 48C in extraction buﬀer (10mM Tris–HCl, pH 8.0,
140mM NaCl, 1.5mM MgCl2, 0.5% Nonidet-P40 and
500U/ml RNAsin), and nuclei were removed by centri-
fugation (12000g,1 0 s ,4 8C). The supernatant was
supplemented with 20mM dithiothreitol, 150mg/ml
cycloheximide, 665mg/ml heparin and 1mM phenyl-
methylsulfonyl ﬂuoride and centrifuged (12000g, 5min,
48C) to eliminate mitochondria. The supernatant was
layered onto a 5ml or a 10ml linear sucrose gradient
(15–40% sucrose [w/v] supplemented with 10mM Tris–
HCl, pH 7.5, 140mM NaCl, 1.5mM MgCl2, 10mM
dithiothreitol, 100mg/ml cycloheximide, and 0.5mg/ml
heparin) and centrifuged in a SW50.1Ti or SW41Ti rotor
(Beckman, Villepinte, France) for 2h at 160000g and at
48C, without brake. Fractions of 300ml were collected and
digested with 100mg proteinase K in 1% SDS and 10mM
EDTA (30min, 378C). RNAs were then recovered by
phenol–chloroform–isoamyl alcohol extraction, followed
by ethanol precipitation. Finally, the fractions containing
the mRNA were precipitated with 2M LiCl on ice at 48C
overnight. After centrifugation (12000g, 15min at 48C),
pellets were washed with 70% ethanol prestored at 208C,
air dried and resuspended in appropriate volumes of
RNAse-free water.
RNAs were analyzed either by electrophoresis on
denaturing 1.2% formaldehyde agarose gels and subse-
quent northern blotting or by cDNA ampliﬁcation as
previously described (43), using speciﬁc VEGF primers
(RTEx4 sens, RT30HA rev).
RESULTS
Previously, we have demonstrated that VEGF can be
generated through both AUG initiated translation
and cleavage of a larger L-VEGF precursor protein
that is initiated from one of multiple upstream, in frame
CUG codons (25). In order to detect diﬀerences between
translational initiation at AUG and CUG codons for each
VEGF mRNA splice variant, we constructed expression
plasmids containing VEGF 121, VEGF 165 or VEGF 189
with mutated signal peptide sequences (40).
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mRNAsequence
Using this approach, we have demonstrated that transla-
tion initiation at a CUG is always eﬃcient regardless of
which splice variant is expressed, whereas initiation at the
AUG depends upon which exons are present in the
mRNA (40). VEGF 121 is expressed through initiation
events using the CUG start codons, which only generate
high molecular weight L-VEGF. In contrast, VEGF 189
and 165 splice variants lead to the production of both
CUG and AUG-initiated proteins (Figure 2A).
To determine how the alternatively spliced VEGF
sequence inﬂuences the initiation-codon choice, we fused
the ﬁrst exon of VEGF, containing the 50UTR, in-frame
AUG start codon and mutated signal peptide, with the
CAT reporter gene and inserted at the 30 end the sequence
corresponding to exons 5 to 8 of VEGF 121, 165 or 189.
Translation initiation still occurred at both CUG codons
and the AUG codon, disregardless of the VEGF sequence
fused at the 30 end (Figure 2B). This shows that the mere
presence of the VEGF 121 isoform speciﬁc primary
sequence was not suﬃcient to reproduce the AUG
blockade. We can conclude that the VEGF 5–8 alternative
exons inﬂuence the choice of the initiation codon only
in the context of the full length VEGF mRNA.
Consequently, we hypothesized that the AUG shut-oﬀ in
the VEGF 121 mRNA depends upon RNA structures that
require continuity from the 50UTR to the vicinity of the
stop codon. These results highlight the role of the full
VEGF mRNA sequence in this regulation and suggest
that there is something speciﬁc within the VEGF 121
isoform sequence that inhibits AUG initiated translation.
Role of the 5’UTR in the VEGF 121 AUG shut-off
mechanism
It was previously established that an alternative promoter
is positioned within the human VEGF 50UTR (15). The
+1 transcription initiation site is located at +633
downstream from the classical start site. Furthermore,
the internal promoter’s insensitivity to hypoxia indicates
that it is used independently of the main promoter region.
Moreover, transcripts initiated from the internal promoter
are of special interest because they cannot encode
L-VEGF isoforms. In addition, these transcripts can
be translated by either a cap-dependent or IRES-A-
dependent mechanism from the AUG codon (15).
The role of the two 50 sequences was investigated by
comparing the expression of each splice variant fused to
the diﬀerent 50UTRs. A deletion of most of the VEGF
50UTR (24 remaining nucleotides) was used as a control
(Figure 3, lanes 2). VEGF 165 and 189 AUG initiated
form was expressed, disregardless of the length of the
50UTR (Figure 3A), while VEGF 121 AUG initiated form
was only detectable from the control construct (Figure 3A,
VEGF 121, lane 2). The integrity of all mRNAs expressed
after transfection was veriﬁed by northern blot
(Supplementary data). Quantiﬁcation of these mRNAs
was determined by RNase protection assays (Figure 3).
For each spliced variant, we can see that VEGF mRNAs
are expressed at comparable levels, indicating that the lack
of the 121 AUG initiated form (Figure 3A lanes 1 and 3) is
due to a posttranscriptional regulation.
To examine this regulation in a more physiological
context, minigene plasmids were constructed (see materi-
als and methods). These minigene constructs should allow,
after alternative splicing of the pre-mRNA, the expression
of the diﬀerent VEGF isoforms. While alternative splicing
generating VEGF 189 was very ineﬃcient in HeLa cells,
results obtained with VEGF 121 and 165 parallel those
obtained with the cDNA constructs (Figure 3B) and only
the construct lacking a 50UTR permitted expression of the
VEGF 121 AUG initiated form (Figure 3B, lane 2). Since
we have previously shown that the half-lives of the VEGF
121, 165, and 189 proteins are very similar (40), we
investigated whether this regulation was exerted through a
translational regulation mechanism and we examined the
association of the diﬀerent transcripts with polysomes.
For transfections using full-length constructs (Figure 4,
lane 1–3), mRNAs associated with polysomes were
recovered. Identical results were obtained with constructs
in which VEGF 165 and 189 transcripts began at the
internal promoter (Figure 4, lanes 4, 5). The same
construction with VEGF 121 clearly showed a very poor
association of this mRNA to polysomes (Figure 4, lane 6).
Because the northern blot is not discriminative enough to
identify the diﬀerent VEGF mRNA isoforms, we analyzed
the VEGF mRNA distribution by RT–PCR after trans-
fection with the IP minigene construct. Interestingly,
VEGF 165 mRNA was present in fractions containing
heavy polysomes, whereas the 121 encoding mRNA was
found to be recovered only in the free mRNA, monosome
and disome fractions (Figure 4, lane 7). These results
corroborate those obtained with cDNA transfections and
reinforce the previous ﬁnding showing that the AUG shut-
oﬀ mechanism of VEGF 121 is independent of the splicing
mechanism.
The minimal 5’region involved in thecontrol ofthe
AUG usagecontainsasmall ORF
A deletion analysis was performed to locate the minimal
sequence responsible for the AUG translational blockade
of VEGF 121 starting with the region between position
633 (IP) and 24 nt upstream from the AUG (Figure 5A). It
is clear that the 200nt upstream from the AUG were
suﬃcient to mediate the speciﬁc AUG blockade of VEGF
121 (Figure 5A, lanes 4) and the region between 100
and 200 was necessary for this eﬀect (Figure 5A, lanes 3
versus 4). These results were conﬁrmed by those obtained
with the minigene constructs (Figure 5A).
It is well documented that the 5’UTRs of vertebrate
mRNAs contain a variety of features that aﬀect the
translation eﬃciency of the main coding sequence (44).
These include the length and putative secondary structures
of the 5’UTR, the sequence context of the initiation codon
as well as the presence of upstream AUG codons
(uAUGs). Interestingly, inspection of the human VEGF
5’UTR revealed the presence of a unique and short uORF
precisely within the region between 200 and 100 nucleo-
tides upstream of the AUG initiation codon. This uORF is
highly conserved between species (Figure 5B) and begins
2440 Nucleic Acids Research, 2008, Vol. 36, No. 7at AUG 852, which is 186 nucleotides upstream from the
main AUG (using the human sequence).
We ﬁrst investigated whether this uORF was translated.
Since it is impossible to visualize the encoded tripeptide,
the uORF stop codon was mutated so that initiation at
the uAUG would generate a 62 AA amino-terminally
extended VEGF. This extended VEGF protein was always
detected (Figure 6, lane 1) demonstrating that the uAUG
was eﬃciently used whatever the splice variant.
A consequence of this construction is the loss of the
VEGF AUG 1038 initiated form.
To gain an insight into the role of the uORF, we
mutated the uAUG. This mutation increased AUG 1038
initiation translation of VEGF 121 isoform, but had no
eﬀect on the VEGF 165 or 189 expression level (Figure 6,
lanes 2 and 3). Remarkably, results obtained with the
minigene construct exactly parallel those achieved with the
cDNA constructs (Figure 6, right panel).
Taken together, these data demonstrate that the uORF
serves as a cis acting regulatory element for VEGF protein
isoform expression.
Translationof the uORF ismostly cap-independent
Since the uORF is located within IRES-A, we investiga-
ted whether the uAUG was translated by a cap- or
VEGF 121 VEGF 165 VEGF 189
+1 IP
AUG
mSP
VEGF 121/165/189
or minigene HA
50
100
200
300
A
VEGF minigene
VEGF 121
VEGF 165
β-actin 
β-actin mRNA
HA  
HA mRNA
β-actin 
β-actin mRNA
HA  
HA mRNA
1 2 3 456
1 23456 1 23456 1 23456
1
2
3
4
5
6
B
Figure 5. Identiﬁcation of the minimal region involved in translation initiation control. (A) Left, schematic representation of the deletion within the
50 leader performed in the IP constructs encoding the three VEGF isoforms and the minigene. Right, expression of AUG-initiated VEGF isoforms
were analyzed by western immunoblotting using an anti-HA antibody. Anti-b-actin was used to control protein loading. RPA analyses were
performed to normalize transfection with a vector speciﬁc probe to quantify mRNA from transfection and with a b-actin probe to control RNA
quantity. (B) Partial alignment of the VEGF mRNA 50 untanslated region of several species. Conserved nucleotides are shown in red. Main VEGF
AUG translation initiation codons (on the right) are framed. The lower part shows a magniﬁcation of the region containing the uORF. The uORF,
extremely well conserved among several species, is positioned in +1 frame relative to the VEGF ORF in human mRNA. This uORF would be
initiated at uAUG (position 852) and be terminated at position 863, 175 nucleotides upstream from the VEGF AUG, and would produce a putative
three amino-acid long polypeptide.
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we performed a knockdown directed against the cap-
binding protein eIF4E using a validated siRNA. As shown
in Figure 7, the eIF4E knockdown inhibited most of the
synthesis of the 121 or 189 control constructs (Ct) in which
the IRES sequences were deleted. Remarkably, expression
from the VEGF 189 AUG in a wild-type (Figure 7, WT)
context was unaﬀected by the inhibition of cap-dependent
translation indicating that the VEGF AUG is completely
IRES-dependent. As expected, the VEGF 121 AUG
initiated form remained undetectable (Figure 7, WT).
Finally, we can see that the uAUG is principally
cap-independent for both the 121 and 189 constructs
(Figure 7, mStop). One can postulate that the uAUG is
able to exhaust small ribosomal subunits recruited at the
cap site, since modest cap-dependent initiation was
detected downstream, at the VEGF AUG (Figure 7,
mStop).
DISCUSSION
VEGF has been shown to be a key mediator of
angiogenesis in diverse physiological and pathological
+1 IP
WT
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mStop
VEGF 121/189
+1
CUG AUG
mSP
HA
uORF
β-actin 
VEGF 189 HA 
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+ − + −
+ − + − + −
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AUG - - - STOP
AUG - - -  - STOP
Figure 7. Translation of the uORF after eIF4E knockdown. Left, schematic representation of construct with uORF mutation (described in the
legend of Figure 6). Right, following eIF4E (+) or control ( ) siRNA transfection, expression of AUG-initiated VEGF 121 and 189 isoforms
constructs (schematized on the left) were analyzed using an anti-HA antibody and anti-b-actin to control loading of protein. Anti-eIF4E was used to
verify knockdown eﬃciency. RPA analyses were performed to normalize transfection with a vector speciﬁc probe to quantify mRNA from
transfection and with a b-actin probe to control RNA quantitation.
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Figure 6. Role of the uORF in the translational initiation control. Left, schematic representation of construct with uORF mutation. The internal
promoter beginning constructs encoding each VEGF isoform or the VEGF minigene either with wild type uORF (pIP121mSPHA, pIP165mSPHA,
pIP189mSPHA and pIPminiVEGF numbered 3), a mutated uORF AUG (pIP121mORFmSPHA, pIP165mORFmSPHA, pIP18mORFmSPHA and
pIPminiVEGFmORF numbered 2) or a mutated uORF stop codon, which made the uORF in frame with the VEGF-HA (pIPmSOmSP121HA,
pIPmSOmSP165HA, pIPmSOmSP189HA and pIPminiVEGFmSO numbered 1). Right, expression of AUG-initiated VEGF isoforms and uORF
were analyzed by western immunoblotting using an anti-HA antibody and anti-b-actin to control loading of protein. RPA analyses were performed
to normalize transfection with a vector speciﬁc probe to quantify mRNA from transfection and with a b-actin probe to control RNA quantitation.
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diabetic retinopathy and tumor development (1,45). The
role of VEGF in developmental angiogenesis is empha-
sized by the ﬁnding that loss of a single VEGF allele (6,7),
as well as modest VEGF overexpression (8) result in
defective vascularization and early embryonic lethality.
Moreover, it has been demonstrated that a single
nucleotide polymorphism in the VEGF gene (634C-G)
results in IRES-B dysfunction and a 17% reduction in
CUG initiated translation and expression of L-VEGF.
This polymorphism was correlated with increased risk in
motor neuron degeneration in amyotrophic lateral sclero-
sis (ALS) (46). Taken together, these ﬁndings clearly show
that a small variation in the level of VEGF can induce
deleterious phenotypes and underline the importance of
VEGF expression regulation both during development
and in the adult.
VEGF gene expression is controlled at many levels
including transcription start sites (10,15), inducibility of
promoters (11–13,15), mRNA stability through the
binding of regulatory proteins to the 30UTR (33–35,38),
mRNA translation via IRES sequences located in the
50UTR (15,28,29) and use of alternative initiation codons
(25–27). These diﬀerent control elements have been
previously characterized and studied independently of
each other. In this work, we have attempted to integrate
several control elements by reconstituting messengers that
possess the original +1 transcription start site, various
50UTRs and the diﬀerent alternatively spliced region
(either as cDNAs or using the genomic sequence). By
this approach, we have revealed another layer in the
already complex translational control of VEGF expres-
sion: the role of a uORF.
Previously, we have demonstrated that diﬀerences in the
exon content between VEGF 121 and VEGF 165/189
control AUG-initiated translation in the larger mRNA.
This mechanism proceeds independently of the 30UTR.
Here, we ﬁrst demonstrated that this control also involves
sequences located in the 50UTR, upstream of the AUG
start codon and downstream of the internal promoter +1
start point (Figure 1). We next identiﬁed that an active
uORF is located within this VEGF region, itself situated
within the IRES-A responsible for this regulation.
Generally, uORFs impose a constitutive barrier to the
scanning ribosome and reduce the number of ribosomes
that gain access to the main AUG codon. In the case of
VEGF, our data have established that the uORF is mostly
translated by a cap-independent mechanism (Figure 7).
Therefore, initiation at the main AUG could be either
directed by the IRES or could be the consequence of
reinitiation after IRES-dependent uORF translation. It
has been established that reinitiation tends to be less
eﬃcient when the intercistronic distance is short or after
translation of long uORFs. The size of the VEGF uORF
(three codons) and the relatively long intercistronic region
(175nt) might, therefore, be predicted to have positive
eﬀects on reinitiation eﬃciency (47). However, our
experimental data suggest that after uORF translation in
the VEGF 121 mRNA, ribosomes could not reinitiate at
the main AUG (Figures 2 and 3). This regulation could be
explained by a modulation of uORF eﬀects due to speciﬁc
conditions involving trans-acting factors that function in
concert with another portion of the messenger. This mode
of action is exempliﬁed by the case of Her-2 mRNA for
which the 30UTR can override translational repression
mediated by a uORF within the 50UTR (48). Speciﬁc
proteins binding to a sequence element within the 30UTR
allow ribosome reinitiation at the main AUG after uORF
translation. These results have deﬁned a novel mechanism
by which translational control of genes harboring a 50
uORF can be modulated by elements located downstream.
Because of the mechanistic resemblance between Her-2
and VEGF, one can hypothesizes that controlled reinitia-
tion takes place during VEGF mRNA translation and
that this control is inhibited in the 121 context. On the
other hand, reinitiation probably only provides a minor
contribution since the mutation of the uAUG in 165 or
189 mRNAs does not generate a signiﬁcant change in the
use of the main AUG (Figure 6).
Alternatively, uORFs translation could aﬀect the local
RNA structure. In the case of the arginine/lysine
transporter (cat-1) mRNA, it has been demonstrated
that induction of IRES activity requires the translation
of a small uORF located within the IRES (49). The
translation of the uORF unfolds an inhibitory structure in
the mRNA leader creating an active IRES through RNA–
RNA interactions between the 50 end of the leader and
downstream sequences (49), which leads to the stimulation
of CAT-1 synthesis. Thus, uORFs have the potential to
aﬀect local RNA structure and could thereby aﬀect
mRNA translation. In the case of VEGF, one can
hypothesize that uORF translation unfolds the IRES
structure eliciting a conformational change. This mod-
iﬁcation only has a minor or transitory consequence for
the 165 and 189 mRNAs, or when the VEGF ORF has
been replaced (Figure 2B). Conversely, an inactive IRES
conformation seems to be locked in the VEGF 121
context. It will be of interest to identify trans-acting
factors [ITAFs, (50)] that could speciﬁcally bind the 165
and 189 mRNAs and stabilize the active structure of the
IRES or, conversely, ITAFs that bind to the 121 form and
lock the IRES in an inactive conformation as previously
described for the FGF-2 IRES, which is silenced by p53
binding (51).
This hypothesis is also supported by the fact that the
majority of VEGF 121 mRNA, initiated at the internal
promoter, cosediments with free mRNAs or monosomes
but not with polysomal fractions (Figure 4). In contrast,
VEGF 165 and 189 mRNAs are distributed throughout
the polysome’s gradient, indicating their eﬃcient transla-
tion (Figure 4). Cooperation of several mRNA segments
might also explain the fact that this negative control could
only be assessable in the context of the wild-type VEGF
mRNA, and not when the VEGF ORF has been replaced
by a reporter gene (Figure 2B).
As suggested by our experimental data, the uORF is not
necessary for IRES formation but is involved in the
speciﬁc AUG shut-oﬀ that exists within the VEGF 121
mRNA.
Our current inability to predict a priori conditions that
alter uORF function means that uORFs, which appear to
be constitutive inhibitors, may turn out to be regulated by
Nucleic Acids Research, 2008, Vol. 36, No. 7 2443speciﬁc sequences, trans-acting factors or conditions that
have not yet been identiﬁed.
The VEGF uORF seems to act as a cis regulatory
element that controls VEGF protein isoform expression.
The important biological properties that distinguish the
VEGF isoforms are their heparin and heparan sulfate
binding aﬃnities. In contrast to VEGF 165 and VEGF
189, VEGF 121 does not bind to the extracellular matrix
and its consequent diﬀusibility endows it with a more
potent angiogenic activity (52). Moreover, it has been
shown by comparing diﬀerential VEGF expression pat-
terns in tumors versus normal cells that there is a shift in
the percentage of VEGF isoforms that are expressed, with
a signiﬁcant increase in VEGF 121 associated with a
decrease of VEGF 165 and 189 in neoplastic cells (53).
In pathological conditions, the hypoxic responsive
promoter is preferentially activated leading to the expres-
sion of a single mRNA that permits IRES-dependent
translation initiation at both CUG codons and the AUG
start codon (Figure 1). We have shown that VEGF 121 is
mainly expressed through initiation events utilizing the
CUG start codons (L-VEGF) followed by maturation of
this amino-terminally extended protein (Figure 1). Hence,
transcriptional activation of this VEGF promoter would
lead to an increased expression of the most diﬀusible
VEGF isoform. Conversely, since the hypoxic responsive
promoter is weakly active during normoxia, the transla-
tional regulation described in this article could represent a
mechanism that rigorously inhibits VEGF 121 synthesis in
noninduced conditions and particularly when the internal
promoter is active.
This work provides additional evidence that the very
high complexity required for the control of VEGF gene
expression necessitates investigation of several control
elements simultaneously (such as uORF, alternatively
spliced sequences, alternative start codons and IRESs).
VEGF, which is regulated at every conceivable stage of
gene expression, represents a paradigm for gene regula-
tion. Regarding this complexity, we are still a long way
from understanding how events both inside and outside
cells work together to control and coordinate VEGF
expression and activity.
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